Picture of Crispr Therapeutics AG logo

CRSP Crispr Therapeutics AG Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Annual income statement for Crispr Therapeutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue413.122900.719915
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses106162243355541
Operating Profit-64.6-15946.7-354374
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-66.6-16467.3-348380
Provision for Income Taxes
Net Income After Taxes-68.4-16566.9-349378
Minority Interest
Net Income Before Extraordinary Items
Net Income-68.4-16566.9-349378
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-68.4-16566.9-349378
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.71-3.441.17-5.294.7

Or unlock with your email

Or unlock with your email